Last update April 27, 2022
Very Low Risk
Eculizumab is a recombinant humanized monoclonal antibody that acts as a complement blocker. It is indicated in paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, optic neuromyeliis and some forms of myasthenia gravis. Weekly intravenous infusion administration.
It is excreted in breast milk in an undetectable or clinically insignificant amount (Miyasaka 2016, Kelly 2015, Sharma 2015, Ando 2014, Sarris 2012) and no problems have been observed in infants of mothers treated with this drug. (Socié 2019, Frairia 2018, Kelly 2015, Sarris 2012)
Furthermore, due to its protein nature, it is inactivated in the gastrointestinal tract without being absorbed (practically nil oral bioavailability) and this hinders or prevents its passage into the infant´s plasma from ingested breast milk (Hale, Lactmed) except for premature infants and during the immediate neonatal period when there might be a greater intestinal permeability.
We do not have alternatives for Eculizumab since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM